HANDOK Inc. (KRX:002390)
South Korea · Delayed Price · Currency is KRW 10,490
-300 (-2.78%)
Apr 2, 2026, 3:30 PM KST
HANDOK Revenue
In the year 2025, HANDOK had annual revenue of 535.14B KRW with 5.48% growth. HANDOK had revenue of 140.05B in the quarter ending December 31, 2025, with 15.48% growth.
Revenue
535.14B
Revenue Growth
+5.48%
P/S Ratio
0.25
Revenue / Employee
569.30M
Employees
940
Market Cap
136.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 535.14B | 27.78B | 5.48% |
| Dec 31, 2024 | 507.36B | -15.38B | -2.94% |
| Dec 31, 2023 | 522.74B | -21.02B | -3.87% |
| Dec 31, 2022 | 543.76B | 26.12B | 5.05% |
| Dec 31, 2021 | 517.64B | 14.03B | 2.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jeil Pharma Holdings | 657.61B |
| Ildong Holdings | 590.89B |
| Dongwha Pharm.Co.,Ltd | 496.39B |
| Kyongbo Pharmaceutical | 264.10B |
| Daihan Pharmaceutical | 208.61B |
| Kukje Pharma | 175.50B |
| CKD Bio | 159.93B |
| REYON Pharmaceutical | 149.34B |